Fundación Gecp

This study tests whether a combination of two drugs (sacituzumab and zimberelimab) can prevent lung cancer from coming back after surgery. It is for people with stage IB to IIIB non-small cell lung cancer whose tumor did not fully disappear after pre-surgery treatment. About 129 …

This study is for people with advanced non-small cell lung cancer whose tumors have high PD-L1 levels. Researchers want to see if a blood test that measures tumor DNA (ctDNA) can help decide whether to add chemotherapy to the immunotherapy drug cemiplimab. About 63 participants w…

This study tests a drug called tarlatamab as a maintenance therapy for people with limited-stage small-cell lung cancer who cannot receive standard concurrent chemo-radiotherapy. After completing sequential chemo-radiation or chemotherapy alone, participants whose cancer has not …

This study tests a pill called sotorasib in people with stage III lung cancer that has a specific KRAS G12C gene change and cannot have standard chemo-radiation. About 19 participants will receive the drug to see if it can delay cancer growth. The goal is to measure how long the …

This study tests a treatment plan for people with stage III non-small cell lung cancer. First, patients receive three cycles of chemotherapy plus the immunotherapy drug atezolizumab. Then, depending on how well the tumor responds, they either have surgery followed by more atezoli…

This study observes how the immune system responds after standard chemo-radiation followed by immunotherapy in patients with stage III non-small cell lung cancer that cannot be removed by surgery. Researchers will review medical records from about 50 participants to see how long …

This study reviews medical records from 150 people with stage IIIA lung cancer who had chemotherapy before surgery. Researchers want to see if the amount of tumor killed by the treatment predicts how long patients live without the cancer coming back. No new treatments are given; …